Matches in Nanopublications for { ?s ?p "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP406171.RA_cegZle8qPTyv8orOGRDvO6esBQPG7mx2mLf6FLaBAo130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP406171.RA_cegZle8qPTyv8orOGRDvO6esBQPG7mx2mLf6FLaBAo130_provenance.
- assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP994008.RASaFZHjtqopJltmiPTLvLbHvHqYxbIs5WJqbUlwXDh9E130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP994008.RASaFZHjtqopJltmiPTLvLbHvHqYxbIs5WJqbUlwXDh9E130_provenance.
- NP994013.RAcHtuqat3qpESE9iHsoSSTew4S0_A1Hr_1KuVfPJmin0130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP994013.RAcHtuqat3qpESE9iHsoSSTew4S0_A1Hr_1KuVfPJmin0130_provenance.
- NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378942.RA-67NxUbLPArHQqijY7D1LS2jORQQ8Bp-82Xaf0IpxK8130_provenance.
- NP380698.RAwiypf5pB0pdhjWUSUfFeD6dS-C11aZ0uYos8O920wqk130_assertion description "[Collectively, these findings show that GBM therapeutic resistance to EGFR inhibitors may be explained by compensatory activation of EGFR-related family members (ERBB2, ERBB3) enabling GBM CSC proliferation, and therefore simultaneous blockade of multiple ERBB family members may be required for more efficacious GBM therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP380698.RAwiypf5pB0pdhjWUSUfFeD6dS-C11aZ0uYos8O920wqk130_provenance.